Clinical trial
Lenalidomide and Melphalan in Treating Patients With Previously Untreated…
NCT00305812 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00305812 |
|---|---|
| Title | Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma |
| Official title | A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | dexamethasone, lenalidomide, melphalan |
| Enrollment | 51 |
| Start date | Mar 9, 2006 |
| Primary completion | Jun 30, 2008 |
| Completion | Jun 30, 2008 |
| First posted | Mar 22, 2006 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: